Lilly launches new product called "The Challenger"

Quote
























Mannkind (the insulin inhaler company) is boldly up 8% today on no news. The old man Mann however, has purchased more shares in his company. What a passionate and honest leader!!!!

Where Pfizer and Lilly failed, MNKD continues to develop it's aerosol insulin. If MNKD succeeds, look out LLY and NOV. This would be the end of LLY's insulin franchise.
 












Anonymous said:
Mannkind (the insulin inhaler company) is boldly up 8% today on no news. The old man Mann however, has purchased more shares in his company. What a passionate and honest leader!!!!

Where Pfizer and Lilly failed, MNKD continues to develop it's aerosol insulin. If MNKD succeeds, look out LLY and NOV. This would be the end of LLY's insulin franchise.
Click to expand...

Apperently you are neither wall street smart, nor insulin research smart. Novo Nordisk (NVO) has outperformed Lly by a big margins.

Risk of nasal / airosol insulin are so huge (acting as a growth factor) they induce epithelial carcinomas (solid tumor, altered alveolar structures) to begin with. No doubt people will see as a big plus, but allergic rhinitis, pulmonary edema, embolism, anosmia are some of the overlooked outcomes. So MANN can develop and secure 100billion dollar market if they want...but it ain't going to happen with insulin or any peptide hormone. Insulin action on non endothelial cell is of a Super Pro Tumor-inducing growth hormone.
 












Smarter than Loss-net, however - you can't beat LOSE-NET when it comes to failure.

"The companies halted enrollment in a study of the drug used in combination with Indianapolis-based Lilly's cancer treatment Alimta and the standard chemotherapy cisplatin as an initial treatment for advanced non-small cell lung cancer. But the companies will allow patients who have already received two or more cycles of the potential drug to remain in the trial. An independent data monitoring committee said those patients appear to have a lower ongoing risk for clotting.

Lilly, based in Indianapolis, and Bristol-Myers, headquartered in New York, are sharing development costs for the drug." --from IndyStar

ACTUALLY MNKD purchased the insulin from ... guess!!!!!!!!!!!!!!!!!!!!!!!!!
 






Top Bottom
Back
Quote